Please login to the form below

Not currently logged in
Email:
Password:

Lemtrada

This page shows the latest Lemtrada news and features for those working in and with pharma, biotech and healthcare.

NICE backtracks on Biogen's multiple sclerosis drug Zinbryta

NICE backtracks on Biogen's multiple sclerosis drug Zinbryta

the disease if they have failed to respond to first-line treatment with Sanofi's Lemtrada (alemtuzumab) or have rapidly evolving severe MS.

Latest news

  • Celebrating excellence Celebrating excellence

    The London-based agency picked up The Cello Health Award for Launch Excellence for work on behalf of Genzyme and its multiple sclerosis treatment Lemtrada. ... Lucid also picked up the Cello Health Award for Launch Excellence Award for supporting Genzyme

  • Lucid behavioural change programmes recognised at PMEA Lucid behavioural change programmes recognised at PMEA

    The London-based agency picked The Cello Health Award for Launch Excellence for work on behalf of Genzyme and its multiple sclerosis treatment Lemtrada. ... Lucid also picked up the Cello Health Award for Launch Excellence Award for supporting Genzyme

  • Sanofi forges $1.5bn cancer partnership with BioNTech Sanofi forges $1.5bn cancer partnership with BioNTech

    and Lemtrada (alemtuzumab) and subsidiary Genzyme's rare disease portfolio.

  • Sanofi plans 18 new product launches by 2020 Sanofi plans 18 new product launches by 2020

    The remainder of its growth portfolio are Cerdelga (eliglustat) for Gaucher disease - the only approved oral, first-line therapy for the rare genetic disease, Lemtrada (alemtuzumab) for multiple sclerosis and sarilumab,

  • Sanofi persuades FDA to back its MS drug Lemtrada Sanofi persuades FDA to back its MS drug Lemtrada

    well-controlled studies that demonstrate the benefits of Lemtrada outweigh its serious adverse effects". ... Lemtrada demonstrated superior efficacy over Rebif on annualised relapse rates in the two studies which were the basis for approval.”.

More from news
Approximately 8 fully matching, plus 25 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Anthill is a specialist digital agency and a strategic partner for life science companies....

Latest intelligence

The Holy Grail of HCP Access
This is the data you need to gain access....
No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....

Infographics